{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:05:19Z","timestamp":1794362719200,"version":"4.9.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.cpcardiol.2025.103019","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T02:57:20Z","timestamp":1739415440000},"page":"103019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hereditary transthyretin amyloidosis (ATTRv)"],"prefix":"10.1016","volume":"50","author":[{"given":"Filippos","family":"Triposkiadis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall C.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios E.","family":"Magouliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Kourek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E","family":"Zakynthinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios K.","family":"Iliodromitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Paraskevaidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-3946","authenticated-orcid":false,"given":"Andrew","family":"Xanthopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.cpcardiol.2025.103019_bib0001","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1021\/bi952501g","article-title":"The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid","volume":"35","author":"Lai","year":"1996","journal-title":"Biochemistry"},{"issue":"22","key":"10.1016\/j.cpcardiol.2025.103019_bib0002","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid Cardiomyopathy: JACC State-of-the-art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.cpcardiol.2025.103019_bib0003","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103019_bib0004","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"14","key":"10.1016\/j.cpcardiol.2025.103019_bib0005","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103019_bib0006","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1007\/s00415-024-12509-8","article-title":"Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variability","volume":"271","author":"Carvalho","year":"2024","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103019_bib0007","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/PL00000791","article-title":"Transthyretin: a review from a structural perspective","volume":"58","author":"Hamilton","year":"2001","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103019_bib0008","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1073\/pnas.091431798","article-title":"Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma","volume":"98","author":"Purkey","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103019_bib0009","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.cpcardiol.2025.103019_bib0010","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1016\/S0021-9258(19)42128-5","article-title":"The amino acid sequence of human plasma prealbumin","volume":"249","author":"Kanda","year":"1974","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103019_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081906","article-title":"The journey of Human transthyretin: synthesis, structure stability, and catabolism","volume":"10","author":"Sanguinetti","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0012","article-title":"The structural understanding of transthyretin misfolding and the inspired drug approaches for the treatment of heart failure associated with transthyretin amyloidosis","volume":"12","author":"He","year":"2021","journal-title":"Front Pharmacol"},{"issue":"15","key":"10.1016\/j.cpcardiol.2025.103019_bib0013","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.febslet.2013.06.016","article-title":"Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors","volume":"587","author":"Zanotti","year":"2013","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0014","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.sbi.2009.12.009","article-title":"Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses","volume":"20","author":"Connelly","year":"2010","journal-title":"Curr Opin Struct Biol"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103019_bib0015","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1110\/ps.8901","article-title":"Transthyretin slowly exchanges subunits under physiological conditions: a convenient chromatographic method to study subunit exchange in oligomeric proteins","volume":"10","author":"Schneider","year":"2001","journal-title":"Protein Sci"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0016","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijcard.2019.10.028","article-title":"Diagnosis of genetic amyloidosis through the analysis of transthyretin gene mutation using high-resolution melting","volume":"301","author":"Lahuerta","year":"2020","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103019_bib0017","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/acn3.51626","article-title":"Amyloidogenicity assessment of transthyretin gene variants","volume":"9","author":"Grether","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2025.103019_bib0018","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s00415-013-7124-7","article-title":"Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy","volume":"260","author":"Dohrn","year":"2013","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103019_bib0019","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506129.2019.1634539","article-title":"Founder effect of the Glu89Gln TTR mutation in the Bulgarian population","volume":"26","author":"Kirov","year":"2019","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s42466-021-00155-8","article-title":"Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis","volume":"3","author":"Dohrn","year":"2021","journal-title":"Neurol Res Pract"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103019_bib0021","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0022","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1006\/bbrc.2000.2554","article-title":"Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M","volume":"270","author":"Almeida","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1242815","article-title":"Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy","volume":"14","author":"Poli","year":"2023","journal-title":"Front Neurol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103019_bib0024","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103019_bib0025","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/cge.12500","article-title":"Frequencies and geographic distributions of genetic mutations in transthyretin- and non-transthyretin-related familial amyloidosis","volume":"88","author":"Zhen","year":"2015","journal-title":"Clin Genet"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0026","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","article-title":"A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"18","author":"Gentile","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132714","article-title":"A phenotypic comparison of the Romanian and French ATTRv cohorts: Glu54Gln founder pathogenic variant vs the most common variants in Western Europe","volume":"419","author":"Neculae","year":"2025","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0028","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jns.12385","article-title":"Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: neurological and cardiological features","volume":"25","author":"Gentile","year":"2020","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103019_bib0029","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003466","article-title":"Presence of the V122I variant of hereditary transthyretin-mediated amyloidosis among self-reported white individuals in a sponsored genetic testing program","volume":"14","author":"Trachtenberg","year":"2021","journal-title":"Circ Genom Precis Med"},{"issue":"23","key":"10.1016\/j.cpcardiol.2025.103019_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033770","article-title":"Hereditary transthyretin amyloidosis in patients referred to a genetic testing program","volume":"13","author":"Bhatt","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103019_bib0031","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.cell.2012.02.022","article-title":"The amyloid state of proteins in human diseases","volume":"148","author":"Eisenberg","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0032","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4161\/pri.2.3.7488","article-title":"Amyloid fibrils: abnormal protein assembly","volume":"2","author":"Rambaran","year":"2008","journal-title":"Prion"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103019_bib0033","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/13506129.2014.964858","article-title":"Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis","volume":"21","author":"Sipe","year":"2014","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/13506120009146820","article-title":"The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000","volume":"7","author":"Kisilevsky","year":"2000","journal-title":"Amyloid"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103019_bib0035","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.3390\/ijms22094429","article-title":"Transthyretin misfolding, A fatal structural pathogenesis mechanism","volume":"22","author":"Si","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"26","key":"10.1016\/j.cpcardiol.2025.103019_bib0036","doi-asserted-by":"crossref","first-page":"14943","DOI":"10.1073\/pnas.261419998","article-title":"The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis","volume":"98","author":"Jiang","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0037","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/13506129.2013.797890","article-title":"Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis","volume":"20","author":"Ihse","year":"2013","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103019_bib0038","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/joim.12585","article-title":"One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition","volume":"281","author":"Suhr","year":"2017","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0039","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1038\/s41467-023-43301-3","article-title":"Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis","volume":"14","author":"Steinebrei","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000132966.36437.12","article-title":"Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy","volume":"63","author":"Koike","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0041","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2018.09.011","article-title":"The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: an ultrastructural study","volume":"394","author":"Koike","year":"2018","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103019_bib0042","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/ane.13035","article-title":"Hereditary transthyretin-related amyloidosis","volume":"139","author":"Finsterer","year":"2019","journal-title":"Acta Neurol Scand"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103019_bib0043","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","article-title":"3rd. Fibril in senile systemic amyloidosis is derived from normal transthyretin","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.cpcardiol.2025.103019_bib0044","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1523\/JNEUROSCI.21-19-07576.2001","article-title":"Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways","volume":"21","author":"Sousa","year":"2001","journal-title":"J Neurosci"},{"issue":"28","key":"10.1016\/j.cpcardiol.2025.103019_bib0045","doi-asserted-by":"crossref","first-page":"17810","DOI":"10.1074\/jbc.272.28.17810","article-title":"Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress","volume":"272","author":"Lander","year":"1997","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103019_bib0046","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103019_bib0047","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"1-2","key":"10.1016\/j.cpcardiol.2025.103019_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.05.018","article-title":"Modifier genes: moving from pathogenesis to therapy","volume":"122","author":"McCabe","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103019_bib0049","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/13506129.2022.2070470","article-title":"A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"29","author":"Coelho","year":"2022","journal-title":"Amyloid"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103019_bib0050","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/eurjpc\/zwae011","article-title":"Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre","volume":"31","author":"Caponetti","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0051","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","article-title":"Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update","volume":"17","author":"Dispenzieri","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0052","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ana.26965","article-title":"Amyloid neuropathy: from pathophysiology to treatment in light-chain amyloidosis and hereditary transthyretin amyloidosis","volume":"96","author":"Chompoopong","year":"2024","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103019_bib0053","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/JND-200490","article-title":"Current view of diagnosing small Fiber neuropathy","volume":"8","author":"Raasing","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"11","key":"10.1016\/j.cpcardiol.2025.103019_bib0054","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1474-4422(17)30329-0","article-title":"The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes","volume":"16","author":"Terkelsen","year":"2017","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103019_bib0055","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4239\/wjd.v6.i2.296","article-title":"Prediabetes diagnosis and treatment: a review","volume":"6","author":"Bansal","year":"2015","journal-title":"World J Diabetes"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103019_bib0056","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncpendmet0142","article-title":"Diabetic neuropathies: clinical manifestations and current treatment options","volume":"2","author":"Vinik","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103019_bib0057","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/13506129.2020.1855134","article-title":"Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience","volume":"28","author":"Ungerer","year":"2021","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103019_bib0058","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/CPJ.0000000000000640","article-title":"Carpal tunnel syndrome and associated symptoms as first manifestation of hATTR amyloidosis","volume":"9","author":"Karam","year":"2019","journal-title":"Neurol Clin Pract"},{"issue":"Suppl 1","key":"10.1016\/j.cpcardiol.2025.103019_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10286-019-00630-y","article-title":"Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review","volume":"29","author":"Gonzalez-Duarte","year":"2019","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0060","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1046\/j.1440-1789.2000.00299.x","article-title":"Pathology of familial amyloidotic polyneuropathy with TTR met 30 in Kumamoto, Japan","volume":"20","author":"Araki","year":"2000","journal-title":"Neuropathology"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103019_bib0061","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0062","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10286-022-00921-x","article-title":"Cardiovascular reflex tests detect autonomic dysfunction in symptomatic and pre-symptomatic subjects with hereditary transthyretin amyloidosis","volume":"33","author":"Guaraldi","year":"2023","journal-title":"Clin Auton Res"},{"issue":"23","key":"10.1016\/j.cpcardiol.2025.103019_bib0063","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.3390\/jcm13237210","article-title":"Amyloids and the heart: an update","volume":"13","author":"Triposkiadis","year":"2024","journal-title":"J Clin Med"},{"issue":"14","key":"10.1016\/j.cpcardiol.2025.103019_bib0064","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jama.2022.2896","article-title":"Association of transthyretin Val122Ile variant with incident heart failure among black individuals","volume":"327","author":"Parcha","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103019_bib0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/13506129.2024.2398446","article-title":"International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction","volume":"31","author":"Yun","year":"2024","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103019_bib0066","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/ehf2.15035","article-title":"Transthyretin cardiac amyloid: broad heart failure phenotypic spectrum and implications for diagnosis","volume":"11","author":"Alonso","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103019_bib0067","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jchf.2022.06.006","article-title":"Racial and genetic differences in presentation of transthyretin amyloid cardiomyopathy with impaired left ventricular function","volume":"10","author":"Martyn","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103019_bib0068","doi-asserted-by":"crossref","first-page":"oead106","DOI":"10.1093\/ehjopen\/oead106","article-title":"Cardiac amyloidosis and aortic stenosis: a state-of-the-art review","volume":"3","author":"Jaiswal","year":"2023","journal-title":"Eur Heart J Open"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103019_bib0069","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3390\/brainsci11080980","article-title":"Renal involvement in hereditary transthyretin amyloidosis: an Italian single-centre experience","volume":"11","author":"Ferraro","year":"2021","journal-title":"Brain Sci"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103019_bib0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/13506129.2015.1015678","article-title":"Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases","volume":"22","author":"Beirao","year":"2015","journal-title":"Amyloid"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103019_bib0071","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/NRL.0000000000000337","article-title":"Current review of leptomeningeal amyloidosis associated with transthyretin mutations","volume":"26","author":"Qin","year":"2021","journal-title":"Neurologist"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0072","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3129\/i09-023","article-title":"Oculoleptomeningeal amyloidosis in 3 individuals with the transthyretin variant Tyr69His","volume":"44","author":"Schweitzer","year":"2009","journal-title":"Can J Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.cpcardiol.2025.103019_bib0073","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10286-019-00628-6","article-title":"Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis","volume":"29","author":"Obici","year":"2019","journal-title":"Clin Auton Res"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103019_bib0074","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103019_bib0075","first-page":"256","article-title":"Invasive and non-Invasive diagnostic pathways in the diagnosis of cardiac amyloidosis","volume":"10","author":"Briasoulis","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"13","key":"10.1016\/j.cpcardiol.2025.103019_bib0076","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","article-title":"Critical comparison of documents from scientific societies on Cardiac amyloidosis: JACC State-of-the-art review","volume":"79","author":"Rapezzi","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103019_bib0077","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13506120600722662","article-title":"Value of renal biopsy in the prognosis of liver transplantation in familial amyloid polyneuropathy ATTR Val30Met patients","volume":"13","author":"Oguchi","year":"2006","journal-title":"Amyloid"},{"issue":"11","key":"10.1016\/j.cpcardiol.2025.103019_bib0078","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1474-4422(23)00334-4","article-title":"Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment","volume":"22","author":"Adams","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0079","doi-asserted-by":"crossref","DOI":"10.1177\/2150132720940519","article-title":"Twenty-four-hour ambulatory blood pressure monitoring","volume":"11","author":"Pena-Hernandez","year":"2020","journal-title":"J Prim Care Community Health"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103019_bib0080","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from phase 2 of the AC-TIVE study, an Italian nationwide survey","volume":"24","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.cpcardiol.2025.103019_bib0081","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.hlc.2019.04.017","article-title":"Echocardiography in infiltrative cardiomyopathy","volume":"28","author":"Perry","year":"2019","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0082","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.amjcard.2023.06.076","article-title":"Echocardiographic longitudinal strain pattern of apical sparing and the search for cardiac amyloidosis: importance of clinical context or \"not all that sparkles is gold\"","volume":"202","author":"Miller","year":"2023","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103019_bib0083","first-page":"261","article-title":"Left atrial strain imaging by Speckle tracking echocardiography: the supportive diagnostic value in cardiac amyloidosis and hypertrophic cardiomyopathy","volume":"10","author":"Monte","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103019_bib0084","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jcmg.2019.06.030","article-title":"Myocardial tissue characterization and fibrosis by imaging","volume":"13","author":"Karamitsos","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103019_bib0085","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0086","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s12350-023-03278-4","article-title":"Quantitative ATTR-cardiac amyloidosis SPECT\/CT imaging: the time is now!","volume":"30","author":"Auer","year":"2023","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103019_bib0087","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jcmg.2020.05.005","article-title":"Quantitative bone-avid tracer SPECT\/CT for cardiac amyloidosis: a crucial step forward","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"10.1016\/j.cpcardiol.2025.103019_bib0088","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","article-title":"Cardiac amyloid quantification using (124)I-evuzamitide ((124)I-P5+14) versus (18)F-Florbetapir: a pilot PET\/CT study","volume":"16","author":"Clerc","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"10.1016\/j.cpcardiol.2025.103019_bib0089","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","article-title":"Cardiac amyloid detection by PET\/CT imaging of iodine ((124)I) evuzamitide ((124)I-p5+14): a phase 1\/2 study","volume":"16","author":"Wall","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103019_bib0090","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1756285612470192","article-title":"Recent advances in the treatment of familial amyloid polyneuropathy","volume":"6","author":"Adams","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"10.1016\/j.cpcardiol.2025.103019_bib0091","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1111\/j.1600-6143.2007.01969.x","article-title":"Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years","volume":"7","author":"Yamamoto","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116424","article-title":"Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS + 7","volume":"405","author":"Dyck","year":"2019","journal-title":"J Neurol Sci"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103019_bib0093","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"30","key":"10.1016\/j.cpcardiol.2025.103019_bib0094","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0095","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/HCO.0000000000000841","article-title":"Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies","volume":"36","author":"Alreshq","year":"2021","journal-title":"Curr Opin Cardiol"},{"issue":"8","key":"10.1016\/j.cpcardiol.2025.103019_bib0096","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40265-019-01129-6","article-title":"Tafamidis: a review in transthyretin amyloidosis with polyneuropathy","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"issue":"26","key":"10.1016\/j.cpcardiol.2025.103019_bib0097","doi-asserted-by":"crossref","first-page":"e38767","DOI":"10.1097\/MD.0000000000038767","article-title":"A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"103","author":"Olatunji","year":"2024","journal-title":"Medicine"},{"issue":"11","key":"10.1016\/j.cpcardiol.2025.103019_bib0098","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin Amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0099","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with Tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103019_bib0100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0101","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial","author":"Judge","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103019_bib0102","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10741-021-10143-4","article-title":"The use of diflunisal for transthyretin cardiac amyloidosis: a review","volume":"27","author":"Ibrahim","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"18","key":"10.1016\/j.cpcardiol.2025.103019_bib0103","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"31","key":"10.1016\/j.cpcardiol.2025.103019_bib0104","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0105","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.amjcard.2023.07.140","article-title":"Safety and efficacy of traditional heart failure therapies in patients with cardiac amyloidosis and heart failure","volume":"204","author":"Yan","year":"2023","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/j.cpcardiol.2025.103019_bib0106","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 Inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0107","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jjcc.2024.03.008","article-title":"Atrial fibrillation in the setting of cardiac amyloidosis - A review of the literature","volume":"84","author":"Bazoukis","year":"2024","journal-title":"J Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0108","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ehf2.13663","article-title":"Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis","volume":"9","author":"Fischer","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103019_bib0109","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/jce.14541","article-title":"Effect of ICD implantation on cardiovascular outcomes in patients with cardiac amyloidosis: a systematic review and meta-anaylsis","volume":"31","author":"Halawa","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ehf2.13701","article-title":"Thromboembolism and bleeding in systemic amyloidosis: a review","volume":"9","author":"Nicol","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"13","key":"10.1016\/j.cpcardiol.2025.103019_bib0111","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2025.103019_bib0112","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/ehf2.13422","article-title":"A case series of cardiac amyloidosis patients supported by continuous-flow left ventricular assist device","volume":"8","author":"Randhawa","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0113","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14797\/mdcj-8-3-8","article-title":"Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management","volume":"8","author":"Estep","year":"2012","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations","volume":"26","author":"Conceicao","year":"2019","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103019_bib0115","first-page":"e69","article-title":"en representacion del Grupo de Trabajo en AA. Recommendations update for the diagnosis and treatment of transthyretin variant amyloidosis (ATTRv)","volume":"163","author":"Gonzalez-Moreno","year":"2024","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0116","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s13023-021-01960-9","article-title":"Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression","volume":"16","author":"Adams","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0117","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.28026","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: recommendations from a panel of experts","volume":"69","author":"Karam","year":"2024","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103019_bib0118","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/archdischild-2016-310459","article-title":"What is CRISPR\/Cas9?","volume":"101","author":"Redman","year":"2016","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"Pt 8","key":"10.1016\/j.cpcardiol.2025.103019_bib0119","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1099\/mic.0.28048-0","article-title":"Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin","volume":"151","author":"Bolotin","year":"2005","journal-title":"Microbiology (Reading)"},{"issue":"7","key":"10.1016\/j.cpcardiol.2025.103019_bib0120","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116636","article-title":"CRISPR-Cas9 system: a new-fangled dawn in gene editing","volume":"232","author":"Gupta","year":"2019","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0122","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/biotech10030014","article-title":"Applications of CRISPR-Cas9 as an advanced genome editing system in life sciences","volume":"10","author":"Tavakoli","year":"2021","journal-title":"BioTech (Basel)"},{"issue":"10","key":"10.1016\/j.cpcardiol.2025.103019_bib0123","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1021\/acs.molpharmaceut.3c00547","article-title":"Differences and similarities of the intravenously administered lipid nanoparticles in three clinical trials: potential linkage between lipid nanoparticles and extracellular vesicles","volume":"20","author":"Suzuki","year":"2023","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.cpcardiol.2025.103019_bib0124","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103019_bib0125","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3390\/ijms25020823","article-title":"CRISPR\/Cas9 as a mutagenic factor","volume":"25","author":"Shumega","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.cpcardiol.2025.103019_bib0126","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-associated reversal of ATTR amyloidosis-related cardiomyopathy","volume":"388","author":"Fontana","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0127","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl B","key":"10.1016\/j.cpcardiol.2025.103019_bib0129","doi-asserted-by":"crossref","first-page":"B79","DOI":"10.1093\/eurheartjsupp\/suad079","article-title":"Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis","volume":"25","author":"Emdin","year":"2023","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275372","article-title":"Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion","volume":"14","author":"Foster","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103019_bib0131","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0132","first-page":"1","article-title":"Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS database","author":"Chen","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"24","key":"10.1016\/j.cpcardiol.2025.103019_bib0133","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.cpcardiol.2025.103019_bib0134","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"10.1016\/j.cpcardiol.2025.103019_bib0135","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J Med Chem"},{"issue":"24","key":"10.1016\/j.cpcardiol.2025.103019_bib0136","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2025.103019_bib0137","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant'Anna","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0138","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/febs.15339","article-title":"Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis","volume":"288","author":"Pinheiro","year":"2021","journal-title":"FEBS J"},{"issue":"17","key":"10.1016\/j.cpcardiol.2025.103019_bib0139","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.cpcardiol.2025.103019_bib0141","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: first Global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0142","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.cpcardiol.2025.103019_bib0143","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.cpcardiol.2025.103019_bib0144","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40265-023-01943-z","article-title":"Vutrisiran: a review in polyneuropathy of hereditary transthyretin-mediated amyloidosis","volume":"83","author":"Nie","year":"2023","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0145","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40120-024-00595-9","article-title":"Impact of baseline neuropathy severity on Vutrisiran treatment response in the phase 3 HELIOS-A study","volume":"13","author":"Luigetti","year":"2024","journal-title":"Neurol Ther"},{"issue":"13","key":"10.1016\/j.cpcardiol.2025.103019_bib0146","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: first Global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103019_bib0147","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103019_bib0148","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides","volume":"23","author":"Ackermann","year":"2016","journal-title":"Amyloid"},{"issue":"15","key":"10.1016\/j.cpcardiol.2025.103019_bib0149","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cpcardiol.2025.103019_bib0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-024-02008-5","article-title":"Eplontersen: first approval","volume":"84","author":"Nie","year":"2024","journal-title":"Drugs"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625000428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625000428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:25:42Z","timestamp":1777350342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280625000428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":150,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0146280625000428"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103019","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hereditary transthyretin amyloidosis (ATTRv)","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103019"}}